SCHEMBL827675

SCHEMBL827675

O=C(NCc1ccccn1)C(F)(F)F

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.67
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
POLB P06746 3/20 0.56
ALDH1A1 P00352 3/20 0.55
KDM4E B2RXH2 1/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
GAA P10253 1/20 0.55
HPGD P15428 3/20 0.55
ALOX15 P16050 2/20 0.54
TDP1 Q9NUW8 1/20 0.54
LMNA P02545 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2D6 P10635 1/20 0.54
MAPT P10636 1/20 0.54
TSHR P16473 1/20 0.54
SORT1 Q99523 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3716649 0.85 L3MBTL1 (0.64) SMN1; SMN2NPC1RAB9AALDH1A1MEN1
SCHEMBL12265783 0.83 SMN1; SMN2 (0.67) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL18415475 0.80 SMN1; SMN2 (1.00) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL29460273 0.80 SMN1; SMN2 (0.79) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL21065524 0.80 SMN1; SMN2 (0.79) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL30522589 0.80 SMN1; SMN2 (1.00) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL2039123 0.80 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL14330463 0.80 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL30602600 0.79 SMN1; SMN2 (0.76) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL243740 0.79 SMN1; SMN2 (0.76) SMN1; SMN2NPC1RAB9APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200227644-A1 ORGANIC LIGHT-EMITTING DIODE OPERABLE AT LOW VOLTAGE WITH HIGH EFFICIENCY AND LONG LIFETIME SFC CO., LTD. (KR) 2020-07-16 US disclosed
EP-3660934-A1 ORGANIC LIGHT EMITTING ELEMENT CAPABLE OF DRIVING AT LOW VOLTAGE AND HAVING HIGH EFFICIENCY AND LONG LIFE CHARACTERISTICS SFC Co., Ltd. (KR) 2020-06-03 EP disclosed
US-8143419-B2 Trisubstituted 1,2,4-triazoles JANSSEN PHARMACEUTICA N. V. (BE) 2012-03-27 US disclosed
US-7745021-B2 Transition metal complex and light-emitting device FUJIFILM CORPORATION (JP) 2010-06-29 US disclosed
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES JANSSEN PHARMACEUTICA N.V. (BE) 2009-10-08 US disclosed
US-7569852-B2 Transition metal complex and light-emitting device FUJIFILM CORPORATION (JP) 2009-08-04 US disclosed
US-20080248329-A1 TRANSITION METAL COMPLEX AND LIGHT-EMITTING DEVICE FUJIFILM CORPORATION 2008-10-09 US disclosed
US-20080116453-A1 TRANSITION METAL COMPLEX AND LIGHT-EMITTING DEVICE FUJIFILM CORPORATION 2008-05-22 US disclosed
US-20080076738-A1 Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds GILEAD SCIENCES, INC. 2008-03-27 US disclosed
US-20080076738-A1 Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds GILEAD SCIENCES, INC. 2008-03-27 US disclosed
US-7329898-B2 Transition metal complex and light-emitting device FUJIFILM CORPORATION (JP) 2008-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076738-A1 Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds TYMP, PNP, PIKFYVE SMN1; SMN2 4116/4885NPC1 1365/4885RAB9A 2959/4885
US-20090253691-A1 TRISUBSTITUTED 1,2,4-TRIAZOLES CHRNA1, CHRNA5, CHRNA3 SMN1; SMN2 3305/4885NPC1 2263/4885RAB9A 1835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.